Management of Patients with Aggressive Pituitary Tumours
Chair Gerard Raverot, France
In July 2015, an ESE Special interest Group was established to propose a definition of aggressive pituitary tumours, develop guidance on therapeutic indication of temozolomide treatment for aggressive pituitary tumours and to evaluate the results of alternative clinical therapies on these tumours.
The SIG carried out a Europe-wide survey of specialists treating patients with aggressive pituitary tumours, asking questions about treatment courses and patient outcomes.
Following the analysis of this survey, a comprehensive literature review was carried out to develop the ESE Clinical Practice Guideline on the Management of Patients with Aggressive Pituitary Tumours, which was present during the European Congress of Endocrinology in 2017 in Lisbon.